These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
422 related articles for article (PubMed ID: 30209161)
21. Circulating Tumor Cell-Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer. Chung JS; Wang Y; Henderson J; Singhal U; Qiao Y; Zaslavsky AB; Hovelson DH; Spratt DE; Reichert Z; Palapattu GS; Taichman RS; Tomlins SA; Morgan TM Neoplasia; 2019 Aug; 21(8):802-809. PubMed ID: 31276932 [TBL] [Abstract][Full Text] [Related]
22. Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. Annala M; Vandekerkhove G; Khalaf D; Taavitsainen S; Beja K; Warner EW; Sunderland K; Kollmannsberger C; Eigl BJ; Finch D; Oja CD; Vergidis J; Zulfiqar M; Azad AA; Nykter M; Gleave ME; Wyatt AW; Chi KN Cancer Discov; 2018 Apr; 8(4):444-457. PubMed ID: 29367197 [TBL] [Abstract][Full Text] [Related]
23. Synaptophysin expression on circulating tumor cells in patients with castration resistant prostate cancer undergoing treatment with abiraterone acetate or enzalutamide. Pal SK; He M; Chen L; Yang L; Pillai R; Twardowski P; Hsu J; Kortylewski M; Jones JO Urol Oncol; 2018 Apr; 36(4):162.e1-162.e6. PubMed ID: 29289429 [TBL] [Abstract][Full Text] [Related]
24. Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. Annala M; Taavitsainen S; Khalaf DJ; Vandekerkhove G; Beja K; Sipola J; Warner EW; Herberts C; Wong A; Fu S; Finch DL; Oja CD; Vergidis J; Zulfiqar M; Eigl BJ; Kollmansberger CK; Nykter M; Gleave ME; Chi KN; Wyatt AW Clin Cancer Res; 2021 Aug; 27(16):4610-4623. PubMed ID: 34083234 [TBL] [Abstract][Full Text] [Related]
25. The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. Halabi S; Guo S; Park JJ; Nanus DM; George DJ; Antonarakis ES; Danila DC; Szmulewitz RZ; McDonnell DP; Norris JD; Lu C; Luo J; Armstrong AJ Clin Cancer Res; 2024 Mar; 30(6):1152-1159. PubMed ID: 38236581 [TBL] [Abstract][Full Text] [Related]
26. Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide. Lolli C; De Lisi D; Conteduca V; Gurioli G; Scarpi E; Schepisi G; Ravaglia G; Menna C; Farolfi A; Altavilla A; Burgio SL; Tonini G; Santini D; De Giorgi U Prostate; 2019 Aug; 79(11):1211-1220. PubMed ID: 31251826 [TBL] [Abstract][Full Text] [Related]
27. Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide. Haas NB; LaRiviere MJ; Buckingham TH; Cherkas Y; Calara-Nielsen K; Foulk B; Patel J; Gross S; Smirnov D; Vaughn DJ; Amaravadi R; Wellen KE; Savitch SL; Majmundar KJ; Black TA; Yee SS; He M; Min EJ; Long Q; Jones JO; Pal SK; Carpenter EL Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):448-456. PubMed ID: 33009489 [TBL] [Abstract][Full Text] [Related]
28. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer. Graham L; Schweizer MT Med Oncol; 2016 May; 33(5):44. PubMed ID: 27042852 [TBL] [Abstract][Full Text] [Related]
29. Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. Lin HM; Mak B; Yeung N; Huynh K; Meikle TG; Mellett NA; Kwan EM; Fettke H; Tran B; Davis ID; Mahon KL; Zhang A; Stockler MR; Briscoe K; Marx G; Crumbaker M; Stricker PD; Du P; Yu J; Jia S; Scheinberg T; Fitzpatrick M; Bonnitcha P; Sullivan DR; Joshua AM; Azad AA; Butler LM; Meikle PJ; Horvath LG EBioMedicine; 2021 Oct; 72():103625. PubMed ID: 34656931 [TBL] [Abstract][Full Text] [Related]
30. Assessment of Total, PTEN Di Lorenzo G; Zappavigna S; Crocetto F; Giuliano M; Ribera D; Morra R; Scafuri L; Verde A; Bruzzese D; Iaccarino S; Costabile F; Onofrio L; Viggiani M; Palmieri A; De Placido P; Marretta AL; Pietroluongo E; Luce A; Abate M; Navaeiseddighi Z; Caputo VF; Celentano G; Longo N; Ferro M; Morelli F; Facchini G; Caraglia M; De Placido S; Buonerba C Clin Genitourin Cancer; 2021 Oct; 19(5):e286-e298. PubMed ID: 33958297 [TBL] [Abstract][Full Text] [Related]
31. Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients. Maillet D; Allioli N; Peron J; Plesa A; Decaussin-Petrucci M; Tartas S; Ruffion A; Crouzet S; Rimokh R; Gillet PG; Freyer G; Vlaeminck-Guillem V Eur Urol Oncol; 2021 Aug; 4(4):609-617. PubMed ID: 31676281 [TBL] [Abstract][Full Text] [Related]
32. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. Scher HI; Lu D; Schreiber NA; Louw J; Graf RP; Vargas HA; Johnson A; Jendrisak A; Bambury R; Danila D; McLaughlin B; Wahl J; Greene SB; Heller G; Marrinucci D; Fleisher M; Dittamore R JAMA Oncol; 2016 Nov; 2(11):1441-1449. PubMed ID: 27262168 [TBL] [Abstract][Full Text] [Related]
33. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Nakazawa M; Lu C; Chen Y; Paller CJ; Carducci MA; Eisenberger MA; Luo J; Antonarakis ES Ann Oncol; 2015 Sep; 26(9):1859-1865. PubMed ID: 26117829 [TBL] [Abstract][Full Text] [Related]
34. Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer. Graf RP; Hullings M; Barnett ES; Carbone E; Dittamore R; Scher HI Eur Urol; 2020 Feb; 77(2):170-177. PubMed ID: 31648903 [TBL] [Abstract][Full Text] [Related]
35. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Bernemann C; Schnoeller TJ; Luedeke M; Steinestel K; Boegemann M; Schrader AJ; Steinestel J Eur Urol; 2017 Jan; 71(1):1-3. PubMed ID: 27471164 [TBL] [Abstract][Full Text] [Related]
36. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer. Belderbos BPS; Sieuwerts AM; Hoop EO; Mostert B; Kraan J; Hamberg P; Van MN; Beaufort CM; Onstenk W; van Soest RJ; Martens J; Sleijfer S; de Wit R; Mathijssen RHJ; Lolkema MP Eur J Cancer; 2019 Nov; 121():48-54. PubMed ID: 31542641 [TBL] [Abstract][Full Text] [Related]
37. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187 [TBL] [Abstract][Full Text] [Related]
38. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Luo J; Attard G; Balk SP; Bevan C; Burnstein K; Cato L; Cherkasov A; De Bono JS; Dong Y; Gao AC; Gleave M; Heemers H; Kanayama M; Kittler R; Lang JM; Lee RJ; Logothetis CJ; Matusik R; Plymate S; Sawyers CL; Selth LA; Soule H; Tilley W; Weigel NL; Zoubeidi A; Dehm SM; Raj GV Eur Urol; 2018 May; 73(5):715-723. PubMed ID: 29258679 [TBL] [Abstract][Full Text] [Related]
39. Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. Crespo M; van Dalum G; Ferraldeschi R; Zafeiriou Z; Sideris S; Lorente D; Bianchini D; Rodrigues DN; Riisnaes R; Miranda S; Figueiredo I; Flohr P; Nowakowska K; de Bono JS; Terstappen LW; Attard G Br J Cancer; 2015 Mar; 112(7):1166-74. PubMed ID: 25719830 [TBL] [Abstract][Full Text] [Related]
40. Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients. Kohli M; Li J; Du M; Hillman DW; Dehm SM; Tan W; Carlson R; Campion MB; Wang L; Wang L; Zhang H; Zhang P; Kilari D; Huang CC; Wang L Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):411-418. PubMed ID: 29858592 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]